Photo from ASCO/LinkedIn
May 2, 2024, 14:30
Glecirasib demonstrates efficacy in KRASG12C-mutated NSCLC – ASCO
American Society of Clinical Oncology (ASCO) shared on X:
“Breaking news from the ASCO Plenary Series:
Glecirasib demonstrates encouraging efficacy and safety in KRASG12C-mutated Non- Small Cell Lung Cancer (NSCLC) in phase 2 trial from China.
ASCO Daily News has more.”
Source: ASCO/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14